Josh Salmans
About Josh Salmans
Josh Salmans is a Scientist I at Prothena Corporation plc, where he has worked since 2022. He has over a decade of experience in research, focusing on amyloidogenic forms of transthyretin and monoclonal antibodies.
Work at Prothena
Josh Salmans currently holds the position of Scientist I at Prothena Corporation plc, a role he has occupied since 2022. Prior to this, he served as an Associate Scientist at the same company from 2012 to 2022, accumulating ten years of experience in the San Francisco Bay Area. His work at Prothena has involved significant contributions to research focused on amyloidogenic forms of transthyretin and monoclonal antibodies targeting these proteins.
Education and Expertise
Josh Salmans earned a Bachelor of Science degree in Genetics and Cell Biology from Washington State University, where he studied from 2004 to 2006. His educational background provides a strong foundation for his research in the field of biotechnology, particularly in the study of amyloid proteins and their implications in various diseases.
Background
Before joining Prothena Corporation, Josh Salmans gained valuable experience in various research roles. He worked as a Research Assistant at Washington State University from 2006 to 2007, followed by a position as Research Associate II at Catalyst Biosciences from 2007 to 2010. He then served as a Senior Research Associate at Neotope Biosciences, a division of Elan Pharmaceuticals Inc, from 2010 to 2012. This diverse background has contributed to his expertise in scientific research.
Research Contributions
Throughout his career, Josh Salmans has contributed to significant research initiatives. He has been involved in studies focusing on amyloidogenic forms of transthyretin and the development of monoclonal antibodies against these proteins. Additionally, he co-authored a publication that discusses the clearance of amyloid deposits by phagocytosis, highlighting his contributions to advancing knowledge in this area.